CEO Message
June 15th, 2020
RLS Global is committed to creating sustainable value for all our stakeholders. Our mission remains, to develop products and procedures that help healthcare professionals to achieve improved treatment outcome and patient quality of life.
RLS GLOBAL’S daily activities are based on the company’s strong values:
Reliability –To deliver consistently good results on commitment and promises
Commitment – RLS cares about our customers, patients and colleagues and we make promises we can keep and deliver
Partnership – We focus on Caring for the Patients, developing efficient and safe products that offer gentle treatment methods
Based on our Unique Buffered Hypochlorite Technology Platform, we develop products with a gentle approach to save healthy tissues. The benefits with the Unique Buffered Hypochlorite technology are:
- Softening damaged or dead tissue
- Making it easier to remove devitalized tissue – a gentle approach to save healthy tissue
- Antimicrobial properties
- Short application time to enable an efficient cleaning procedure
I believe, despite current circumstances RLS has managed to coordinate the business well during this spring. Since the healthcare sector is extremely strained these days, RLS focuses even more on R&D activities. RLS has an extensive clinical program in place working in close cooperation with leading Hospital Universities to drive the science and development forward. To work together with leading healthcare professionals is key to secure the outcome of the development of new products and therapies.
SOME WORDS ABOUT Wound Management
Before ending my CEO letter, I would like to mention the importance of what to think about when it comes to Wound Management. Accurate wound assessment and effective wound management requires an understanding of the patients underlaying disease, the physiology of wound healing, combined with knowledge of efficient wound management. It is essential that an ongoing process of assessment, clinical decision making, intervention and documentation occurs to facilitate optimal wound healing. Based on the evidence and current state of practice, a well-planned and systematic approach to wound cleansing is needed. To inform and to educate about efficient debridement is one of our focus areas. ChloraSolv is an advancement in treatment of patient with diabetic foot ulcers.
Mölndal, June 15th, 2020
Karin Fischer
CEO

RLS Global is committed to creating sustainable value for all our stakeholders. Our mission remains, to develop products and procedures that help healthcare professionals to achieve improved treatment outcome and patient quality of life.
RLS GLOBAL’S daily activities are based on the company’s strong values:
Reliability –To deliver consistently good results on commitment and promises
Commitment – RLS cares about our customers, patients and colleagues and we make promises we can keep and deliver
Partnership – We focus on Caring for the Patients, developing efficient and safe products that offer gentle treatment methods
Based on our Unique Buffered Hypochlorite Technology Platform, we develop products with a gentle approach to save healthy tissues. The benefits with the Unique Buffered Hypochlorite technology are:
- Softening damaged or dead tissue
- Making it easier to remove devitalized tissue – a gentle approach to save healthy tissue
- Antimicrobial properties
- Short application time to enable an efficient cleaning procedure
I believe, despite current circumstances RLS has managed to coordinate the business well during this spring. Since the healthcare sector is extremely strained these days, RLS focuses even more on R&D activities. RLS has an extensive clinical program in place working in close cooperation with leading Hospital Universities to drive the science and development forward. To work together with leading healthcare professionals is key to secure the outcome of the development of new products and therapies.
SOME WORDS ABOUT Wound Management
Before ending my CEO letter, I would like to mention the importance of what to think about when it comes to Wound Management. Accurate wound assessment and effective wound management requires an understanding of the patients underlaying disease, the physiology of wound healing, combined with knowledge of efficient wound management. It is essential that an ongoing process of assessment, clinical decision making, intervention and documentation occurs to facilitate optimal wound healing. Based on the evidence and current state of practice, a well-planned and systematic approach to wound cleansing is needed. To inform and to educate about efficient debridement is one of our focus areas. ChloraSolv is an advancement in treatment of patient with diabetic foot ulcers.
Mölndal, June 15th, 2020
Karin Fischer
CEO
About us
RLS Global is a Swedish MedTech company based in Gothenburg, founded in 1996. Through our advanced and unique Buffered Hypochlorite Technology Platform we focus on developing products based on Gentle methods for Minimally Invasive Treatment.
Strategy & Values
Through our advanced and unique technology platform we provide Minimally Invasive Treatment which provides quality of life for patients worldwide.
Newsletter
We invite you to read the latest news about our initiatives and company activities.
Career
We are honest and caring for our customers, patients and colleagues. We only make promises that we can keep and deliver. Together, we form a winning Team.
About RLS Global
RLS Global is a Swedish MedTech company based in Gothenburg, founded in 1996. Through our advanced and unique Buffered Hypochlorite based Technology Platform we focus on developing products based on Gentle methods for Minimally Invasive Treatment.
Visit us
RLS Global AB
Neongatan 5
SE 431 53 Mölndal
Sweden

Contacts
Customer Services & Orders:
+46 31 780 68 20
customer@rlsglobal.com
Office
+46 31 780 68 20
customer@rlsglobal.com